Evotec and Haplogen have signed a collaboration agreement to discover and develop small molecules against viral infectious diseases. Financial terms were not disclosed.   The companies will co-develop drugs against a human protein that is essential for pathogenic viruses to infect their host cell. This protein was discovered by Haplogen’s technology that identifies host factors for infectious pathogens. Evotec will further develop lead compounds and apply its drug discovery platform to find addi...